Perrigo recalling more than 162,500 tubes of acne gel

Perrigo building
Perrigo is recalling 162,534 tubes of an acne gel in the U.S.

Perrigo, already facing pressure from activist investors, is also dealing with another recall, this time for a prescription acne med that has some mold issues.

According to the most recent FDA Enforcement Report, the Dublin-based company several weeks ago began voluntarily recalling 10 lots of clindamycin phosphate and benzoyl peroxide gel. That amounts to 162,534 tubes of the generic version of Duac Gel.

The report says that a small number of tubes of the nonsterile gel may include the presence of mold on the cap. The med is manufactured at a Perrigo plant in Israel.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Perrigo had several significant recalls last year, including 200 million doses of a medication used to fight infections like diaper rash and thrush after a labeling mishap. It also recalled its copy of children's grape-flavored Mucinex after learning that dosing cups may be mismarked, putting children at risk for being overdosed.  

Perrigo has been under pressure from Starboard Value, a hedge fund that owns about 4.6% of the company and which has slammed Perrigo's “woeful” performance. In December, Perrigo said one step it would take to improve its margins was to restructure its Omega Pharma Belgium business. As part of that move, it expects to cut about 80 jobs.


Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.